ClinicalTrials.gg
RecruitingNCT05939531BOUNCEUpdated Jan 25, 2024

Multi-domain Intervention Program for Post-stroke Bone Health in Older Adults (BOUNCE)

An interventional study of BOUNCE Program and Standard Care in Bone Loss, Stroke and Geriatrics, sponsored by Hospital Pengajar Universiti Putra Malaysia. Recruiting at 1 site in Malaysia. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-01-25.

Sponsored by Hospital Pengajar Universiti Putra Malaysia · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

The goal of this feasibility randomized controlled trial is to assess the feasibility and compare the changes in bone mineral density before and after the intervention in post-stroke older adults. The main question[s] it aims to answer are:

  • What are the baseline sociodemographic and bone health characteristics of post-stroke older adults in this study?
  • Is it feasible to undertake a larger RCT to assess the effectiveness and implementation of BOUNCE program?
  • Is there a difference in bone loss between groups?
  • Is there a difference in bone turnover markers at baseline and at six months?
  • Is there a difference in the incidence of falls and fragility fractures between groups?
  • How receptive are post-stroke patients/carers to the use of food/exercise diary?
  • What are the perceived motivators and barriers to implementation of BOUNCE program within real clinical settings among healthcare professionals, participants and carers?
  • What is the experience of healthcare professionals, participants and carers undergoing BOUNCE program?

Participants will be divided into two groups:

  1. Standard care
  2. Intervention group (BOUNCE Program) Researchers will compare both groups to see any changes in the bone mineral density and bone turnover markers before and after the intervention.
Read the detailed description

Stroke causes secondary osteoporosis, falls and fractures. The 2020 Malaysian Stroke Guideline recommends fall and fracture risk assessment in all older stroke patients, but it does not make a firm recommendation on the interventions to address post-stroke bone loss. Stroke increased the risk of fall by 1.5 times compared to the normal population and quadrupled the risk of fracture. Hip fractures will increase the cost for treatment, hospitalization, operation and complicate the rehabilitation process from the stroke itself.

Hence, our study aims to develop and assess the feasibility of a multi-domain intervention (BOUNCE program) for bone health among older adults with acute stroke. A multi-domain non-pharmacological intervention is proposed due to the complex nature of bone loss in older post-stroke patients such as low serum Vitamin D, sarcopenia, frailty, comorbidity, ageing and hemiparesis. Therefore, this study is designed through the 2021 MRC Framework of Developing and Evaluating Complex Intervention and is divided into 3 phases. The first phase is a systematic review to identify evidence on non-pharmacological interventions for post-stroke bone health. Phase 2 is the development and validation of a novel multi-domain intervention protocol for BOUNCE program through an expert consensus development conference. The final phase will be a feasibility trial of BOUNCE program, which is further divided into two components. The first component is a randomized, controlled, single-blinded feasibility trial (RCT) of 6-months intervention (BOUNCE program) versus standard care, which primarily assesses bone loss through bone mineral density and bone turnover markers. The second component is a qualitative analysis through Focused Group Discussions on the feasibility of BOUNCE program among healthcare professionals, patients and carers. The outcome of this study will inform the next step of evaluation, which is a future full RCT to assess the effectiveness and economic studies before it can be implemented widely.

02

Conditions studied

  • Bone Loss
  • Stroke
  • Geriatrics

Keywords

  • Feasibility
  • Bone Loss
  • Intervention
  • Geriatrics
  • Stroke
03

In context

Bone Diseases, Metabolic

663 studies on the registry are indexed under Bone Diseases, Metabolic; 95 are open to participants now.

This study's planned enrollment of 70 is above the median of 60 across 510 interventional studies indexed under Bone Diseases, Metabolic.

Browse Bone Diseases, Metabolic studies →

Lead sponsor

Hospital Pengajar Universiti Putra Malaysia is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 50 years old and older
  • Neurologist diagnosed acute stroke within 90 days
  • Has baseline biochemical test upon admission to the ward
  • Able to undergo DXA scan
  • Modified Rankin Score of 2 to 3
  • Able to walk with or without aids

Exclusion criteria

Exclusion Criteria:

  • Known underlying
  • Known major depression or severe psychological illness
  • Known chronic kidney disease stage 3b ( \<45ml/min/1.73m2) or more
  • Taken oral therapy for at least three months
  • Presence of cognitive impairment (ECAQ \<7)
  • Presence of coronary artery syndrome or congestive cardiac failure
  • Presence of an uncontrolled respiratory condition
  • Underlying malabsorption syndrome
  • Underlying conditions other than stroke that impairs mobility (eg Severe Osteoarthritis, Parkinson's Disease, Multiple sclerosis)
  • Known osteoporosis or fragility fracture
  • Serum phosphate or calcium abnormalities
  • Discharge to a nursing home or rehabilitation centre
  • Already a participant in another trial/study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Standard Care

    Standard post-stroke care

    Behavioral: Standard Care

  • Experimental
    Intervention

    BOUNCE Program

    Behavioral: BOUNCE Program

Interventions

  • BehavioralBOUNCE Program

    Intervention arm: Bone-building exercises will be incorporated into the standard post-stroke exercises, as well as Nutritional intervention consisting of individualized diet plan based on calorie requirement, high-quality protein intake, vitamin D, Calcium and micronutrients with a one-to-one virtual session.

  • BehavioralStandard Care

    Standard post-stroke care

06

What researchers measure

Primary outcomes

  1. Change in Areal Bone Mineral Density (BMD) at the Neck of Femur as measured by Hologic Dual X-ray Absorptiometry in g/cm2

    To examine the difference in Areal BMD change pre and post-intervention between groups

    Time frame: At baseline and month-6

Secondary outcomes

  1. Recruitment uptake

    Number of participants randomized among screened

    Time frame: Throughout study period of average 1 year

  2. Change in the level Bone Turnover Markers (BTM) as assessed by C-Telopeptide-Cross-Linked Type I Collagen (CTx) in ng/ml and Procollagen Type I N-Terminal Propeptide (PINP) in ng/ml

    To examine the difference of BTM change pre and post-intervention between groups

    Time frame: At baseline and month-6

  3. Retention

    Number of participants followed-up among randomized

    Time frame: Assessment at month-4 and month-6

  4. Treatment adherence

    Number of participants who adhere to the nutritional and exercise interventions in each group

    Time frame: Assessment at month-4 and month-6

  5. Acceptability

    Qualitative study using semi-structured interviews (3 Focus group discussions consist of 10 participants, 10 healthcare professionals and 10 carers) on the motivators, barriers and experience of the intervention

    Time frame: Assessment at month-4 and month-6

  6. Side-effects

    Qualitative study using a semi-structured interview on any side effects of the intervention

    Time frame: Assessment at month-4 and month-6

  7. Falls

    Number of participants experiencing falls during the study period as assessed by Falls Diary

    Time frame: Assessment at month-4 and month-6

  8. Fracture

    Number of participants experiencing bone fragility fracture during the study period as assessed by x-ray evidence

    Time frame: Assessment at month-4 and month-6

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Nov 2024, 20 months after the start.

Of 161 non-industry interventional studies with no phase under Bone Diseases, Metabolic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 20 months is close to that.

Counting every sponsor, half of 177 studies reached it within 22 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2023
First posted
Jul 11, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Nov 30, 2024
CompletionEst.
Aug 31, 2025
Last update
Jan 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05939531
Lead sponsor
Hospital Pengajar Universiti Putra Malaysia
Collaborators
Ministry of Higher Education, Malaysia
Responsible party
Sponsor
First posted
Jul 11, 2023
Start date
Mar 1, 2023
Primary completion
Nov 30, 2024 (estimated)
Completion
Aug 31, 2025 (estimated)
Last update
Jan 25, 2024

Study contacts

Hakimah Mohammad Sallehuddin, MBBS
Contact
drhakimah@upm.edu.my
+60397692893 ext. 2568
Sazlina Shariff-Ghazali, PhD
study chair · Universiti Putra Malaysia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion